Neuphoria Therapeutics Pre-Tax Profit Margin 2022-2024 | NEUP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Neuphoria Therapeutics pre-tax profit margin from 2022 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Neuphoria Therapeutics Pre-Tax Profit Margin 2022-2024 | NEUP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Neuphoria Therapeutics pre-tax profit margin from 2022 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$139.4B
Bristol Myers Squibb (BMY)	$115.2B
Gilead Sciences (GILD)	$114.5B
Vertex Pharmaceuticals (VRTX)	$104.5B
CSL (CSLLY)	$84.4B
Regeneron Pharmaceuticals (REGN)	$78.6B
GSK (GSK)	$70.4B
Argenex SE (ARGX)	$37.4B
Alnylam Pharmaceuticals (ALNY)	$30.1B
BioNTech SE (BNTX)	$27.6B
Biogen (BIIB)	$21.9B
Illumina (ILMN)	$20.8B
BeiGene (ONC)	$18B
Moderna (MRNA)	$16.2B
Genmab (GMAB)	$13.9B
Incyte (INCY)	$13.4B
BioMarin Pharmaceutical (BMRN)	$12.7B
Insmed (INSM)	$12.5B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.4B
Exact Sciences (EXAS)	$10.5B
Vaxcyte (PCVX)	$10.4B
QIAGEN (QGEN)	$10.2B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.9B
Roivant Sciences (ROIV)	$8.8B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8B